KalshiCheck availabilityKYC requiredVerified resolution dataWell calibratedSelected book midpoint
Before 2027 · —
Loading selected book…
—
Stored price
Before 2027 21%Leader of 3 outcomes
Before 2027 21%Market quality
58 / 100
Medium quality24h Volume
$277.3
Open interest
$41.7K
High open interestBid / Ask
— / —
Before 2027Spread
—
Market data
Updated 8 minutes ago
Mar 24, 26, 2:00 PM UTCJan 1, 27, 4:59 AM UTC
Chart and changes show stored historical probabilities, not the selected live book.
Trends
Selected row: book midpoint. Other rows: stored references, possibly normalized; 24h changes use stored history.
Before SeptemberLost
Venue terms
Source: Kalshi
Informational venue terms only; CoinRithm paper trading uses its own rules.
- Early close:
- Yes
- Settlement timer:
- 30m (informational)
Market depth · Before 2027
Loading selected book…
—
Related Markets
Related questions for context, not a comparison of equivalent contracts.
Will the ACA premium tax credits be extended?
KalshiHantavirus pandemic in 2026?
PolymarketSkin cancer vaccine BLA submitted by which date?
PolymarketHow many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
PolymarketHantavirus pandemic in 2026? [Polymarket]
Manifold MarketsWhat will the average number of measles cases be during Trump's term?
KalshiRules
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.
Settles via:Food and Drug Administration
- The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility. Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
Rules for each outcome
- Before 2027
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.
- Before November
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Nov 1, 2026, then the market resolves to Yes.
- Before September
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.